Document is current

Article History

Received: 5 September 2023

Accepted: 22 November 2023

First Online: 28 December 2023

Declarations

:

: NTU reports consulting roles for AstraZeneca, Bayer, Pfizer, Gilead Sciences, Chugai Pharmaceutical, CytoDyn, Daiichi-Sankyo, DynaMed, Eisai, KeChow Pharma, Lavender Health, OBI Pharma, OncoCyte, Ourotech D/B/A Pear Bio, Kirilys Therapeutics, Peptilogics, Phoenix Molecular Designs, Preferred Medicine, Puma Biotechnology, Sumitomo Dainippon Pharma, Sysmex, Takeda Pharmaceuticals, Unitech Medical, CARNA Biosciences, ChemDiv, DualityBio, LARVOL, Oncolys BioPharma, Rakuten Medical, Merck, AnHeart Therapeutics, Carisma Therapeutics, and Therimunex; speaker or preceptorship roles for Bristol Myers Squibb, CareNet, Chugai Pharmaceutical, Genomic Health, Kyowa Hakko Kirin, Sumitomo Dainippon Pharma, and Medscape; and research agreements with AnHeart Therapeutics, Eisai, Gilead Sciences, Phoenix Molecular Designs, Daiichi-Sankyo, Puma Biotechnology, Merck, Oncolys BioPharma, OBI Pharma, ChemDiv, Tolero Pharmaceuticals, and VITRAC Therapeutics. Institutional database support was received from the Morgan Welch Inflammatory Breast Cancer Research Program, and a State of Texas Rare and Aggressive Breast Cancer Research Program Grant. JB reports serving as an educational speaker for Varian; receiving royalties from Wolters Kluwer; and receiving honoraria from Oncoclinicas and MJH Life. MT reports receiving conference travel and accommodations support from Endomag. Institutional database support was received from the Morgan Welch Inflammatory Breast Cancer Research Program, and a State of Texas Rare and Aggressive Breast Cancer Research Program Grant. GJW reports a consulting role for Siemens and serving as an editor for UpToDate. WW reports consulting roles for Exact Sciences and Epic Science; and receiving institutional database support from the Morgan Welch Inflammatory Breast Cancer Research Program, and a State of Texas Rare and Aggressive Breast Cancer Research Program Grant. BO reports clinical trial support from Incyte Corp. and Eisai. SMT reports consulting or advisory roles for Novartis, Pfizer, Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, Seattle Genetics, CytomX Therapeutics, Daiichi-Sankyo, Gilead, Ellipses Pharma, 4D Pharma, OncoSec Medical Inc., BeyondSpring Pharmaceuticals, OncXerna, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, ARC Therapeutics, Infinity Therapeutics, Myovant, Zetagen, Umoja Biopharma, Artios Pharma, Menarini/Stemline, Aadi Biopharma, Bayer, Incyte Corp, and Jazz Pharmaceuticals; and research funding from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, Gilead, NanoString Technologies, Seattle Genetics, and OncoPep. MR reports institutional research funding from AstraZeneca, Bayer, Bristol-Myers Squibb, DebioPharm, Ipsen, Novartis, Pfizer, Roche, and TerSera Therapeutics; and consulting or advisory roles for AstraZeneca, Bristol-Myers Squibb, DebioPharm, Ipsen, TerSera Therapeutics, and Tolmar Pharmaceuticals. FL reports consulting/advisory roles for AstraZeneca, Pfizer, Merck and Daiichi-Sankyo; and institutional research funding from Eisai, AstraZeneca, CytomX and Gilead Sciences. RL reports a consulting role for Gilead; serving on the advisory board for Biotheryx; serving on advisory boards for, and receiving research support from, Eli Lilly, Novartis, and Celcuity; and receiving research support from Accutar Biotechnology, Inc., Pfizer, Puma, Zentalis, and Arvinas.

: This study was conducted in line with the principles of the Declaration of Helsinki. Approval was granted by the Dana-Farber/Harvard Cancer Center Institutional Review Board (protocol 21–684). This was a retrospective study, so participants were not required to provide consent.